MiNA Therapeutics Denmark ApS
APSDissolvedCVR 43329545Frederikskaj 10B, 2450 København SVManufacture of pharmaceutical preparations· NACE 2120Est. 2022 · 4 years old2 employees
Loading company…
Overview
MiNA Therapeutics Denmark ApS is a Danish APS based in København SV, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 2022, the company has 2 employees and reported a gross profit of DKK 4.7m in its latest annual filing.
Gross profit 2024
4.7M DKK
−58% vs 2023
EBITDA margin (of gross profit)
10.8 %
−93% vs 2023
Net profit 2024
0.4M DKK
-94% vs 2023
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
21.1 %
WeakAmong the 30% lowest rated companies in the industry
20222024
Liquidity ratioCurrent assets ÷ Short-term debt
3.3×
StrongAmong the 30% highest rated companies in the industry
20222024
Return on assets (ROA)Net profit ÷ Total assets × 100
6.1 %
AverageAround the average of companies in the same industry
20222024
EBITDA — year on year
DKK thousandsKey figures
Annual report 2024| Gross profit | 4.7M DKK | -58% |
| EBITDA | 0.5M DKK | -93% |
| Net profit | 0.4M DKK | -94% |
| Total assets | 6.1M DKK | +183% |
| Equity | 1.3M DKK | +41% |
| Employees | 2 | — |
Company information
Legal name
MiNA Therapeutics Denmark ApS
CVR number
43329545
Legal form
Anpartsselskab
NACE code
Founded
15 June 2022 · 4 years
Share capital
DKK 40,000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af et bestyrelsesmedlem.
Address
Frederikskaj 10B, 2450 København SV
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2024), MiNA Therapeutics Denmark ApS reported a gross profit of DKK 4.7m, a decrease of 58% on the year before. The figures on this page draw on 3 annual filings covering 2022 to 2024. The bottom line showed a net profit of DKK 372.5k, and the EBITDA margin stood at 10.8%.
At the end of 2024, equity financed 21.1% of the balance sheet, and current assets covered short-term debt 3.3 times.
Financials
Gross profit
DKK millionsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Gross profit | 4,727 | 11,343 | -1,014 |
| Staff expenses | -4,217 | -4,461 | -4,729 |
| EBITDA | 510 | 6,882 | -5,743 |
| Depreciation & amort. | -7 | -8 | -9 |
| EBIT | 503 | 6,875 | -5,752 |
| Net financials | -18 | -3 | -1 |
| Profit before tax | 486 | 6,871 | -5,753 |
| Tax | 113 | 247 | -0 |
| Net profit | 373 | 6,624 | -5,753 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total assets | 6,069 | 2,142 | 400 |
| Equity | 1,284 | 911 | -5,713 |
| Long-term debt | 2,954 | 0 | 5,406 |
| Short-term debt | 1,831 | 1,231 | 707 |
| Total debt | 4,785 | 1,231 | 6,113 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
10.8 %
20222024
Equity ratio
21.1 %
WeakAmong the 30% lowest rated companies in the industry
20222024
Return on equity
29.0 %
StrongAmong the 40% highest rated companies in the industry
20222024
Net profit margin (of gross profit)
7.9 %
20222024
Asset turnover (of gross profit)
0.78×
20222024
Debt / equity
3.73×
Very weakAmong the 20% lowest rated companies in the industry
20222024
Sector performance
23 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Strong
Among the 40% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Strong
Among the 30% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Average
Around the average of companies in the same industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioAverage
Around the average of companies in the same industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Liquidity
Current ratioStrong
Among the 30% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 20% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioAverage
Around the average of companies in the same industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 20% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 30% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 30% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 20% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 20% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtAverage
Around the average of companies in the same industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageStrong
Among the 30% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 40% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginStrong
Among the 40% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalVery strong
Among the 20% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 20% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (5)
PJ Management | Management | 2022 – 2024 |
RJ Management | Management | 2022 – 2026 |
RS Management | Management | 2022 – 2026 |
TK Management | Management | 2022 – 2024 |
NA Management | Management | 2022 – 2024 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|
Former (12)
SC Board of Directors | Board of Directors | 2022 – 2026 |
PJ Board of Directors | Board of Directors | 2022 – 2026 |
SG Board of Directors | Board of Directors | 2025 – 2026 |
CB Board of Directors | Board of Directors | 2022 – 2023 |
KR Board of Directors | Board of Directors | 2022 – 2022 |
RC Board of Directors | Board of Directors | 2022 – 2026 |
YG Board of Directors | Board of Directors | 2025 – 2025 |
RS Board of Directors | Board of Directors | 2022 – 2026 |
NW Board of Directors | Board of Directors | 2025 – 2026 |
RI Chairman | Chairman | 2023 – 2026 |
GY Board of Directors | Board of Directors | 2022 – 2025 |
NA Chairman | Chairman | 2022 – 2023 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
MiNA (Holdings) Limited | Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
MiNA (Holdings) Limited100%
MiNA Therapeutics Denmark ApS (this company)Board network connections
Board members of MiNA Therapeutics Denmark ApS also hold positions in 1 other company.
| Person | Role here | Other companies |
|---|---|---|
| Troels Koch | Management | 1 company |
Frequently asked questions
What is the CVR number of MiNA Therapeutics Denmark ApS?
MiNA Therapeutics Denmark ApS is registered with CVR / Virk under CVR 43329545.
What is the gross profit of MiNA Therapeutics Denmark ApS?
MiNA Therapeutics Denmark ApS reported a gross profit of DKK 4.7m in 2024.
How many employees does MiNA Therapeutics Denmark ApS have?
MiNA Therapeutics Denmark ApS employs 2 people as of the latest annual report.
Where is MiNA Therapeutics Denmark ApS headquartered?
MiNA Therapeutics Denmark ApS's registered address is Frederikskaj 10B, 2..